Anti-androgens for COVID-19

philipn authored on March 11, 2021, 5:17 p.m.

Review changes View this version of the page

You can also use the and keys

~~Deletions are marked like this~~	Additions are marked like this
	Anti-androgens are a proposed COVID-19 therapeutic. Anti-androgens are drugs that either block the binding of ligands at the androgen receptor or block the production of androgens in the body. Possible mechanism of benefit in COVID-19 Add here. TMPRSS2 is proposed. Clinical trial results N=588 double-blind, randomized controlled trial of proxalutamide in Brazil reported a > 90% reduction in mortality in hospitalized COVID-19 patients in an early press release: The preliminary analysis conducted on March 9, 2021 was based on 294 patients (56.8% male) inthe Proxalutamide arm and 296 patients (57.8% male) in the control arm. According to the results on day 14, the mortality in Proxalutamide arm was 11(3.7%), compared to 141 (47.6%) in control arm, demonstrating a reduced mortality risk of 92%. The number of new mechanical ventilation (MV) and/ordeath in Proxalutamide arm was 13 (4.4%), compared to 156 (52.7%) in control arm, reducing mortality risk by 92%; and median hospital length stay (days) in Proxalutamide arm was 5, while it was 14 in control arm, which means Proxalutamide shortened hospital stay by 9 days. List of clinical trials Enzalutamide Treatment in COVID-19 (COVIDENZA) Randomized Open Label Phase II Study to Evaluate the Efficacy of Enzalutamide in High Risk Male Outpatients With COVID-19 EAT-DUTA AndroCoV Trial See also COVID-19 therapeutics

~~Deletions are marked like this~~

Additions are marked like this

Anti-androgens are a proposed COVID-19 therapeutic. Anti-androgens are drugs that either block the binding of ligands at the androgen receptor or block the production of androgens in the body.

Possible mechanism of benefit in COVID-19

Add here. TMPRSS2 is proposed.

Clinical trial results

N=588 double-blind, randomized controlled trial of proxalutamide in Brazil reported a > 90% reduction in mortality in hospitalized COVID-19 patients in an early press release:

The preliminary analysis conducted on March 9, 2021 was based on 294 patients (56.8% male) inthe Proxalutamide arm and 296 patients (57.8% male) in the control arm. According to the results on day 14, the mortality in Proxalutamide arm was 11(3.7%), compared to 141 (47.6%) in control arm, demonstrating a reduced mortality risk of 92%. The number of new mechanical ventilation (MV) and/ordeath in Proxalutamide arm was 13 (4.4%), compared to 156 (52.7%) in control arm, reducing mortality risk by 92%; and median hospital length stay (days) in Proxalutamide arm was 5, while it was 14 in control arm, which means Proxalutamide shortened hospital stay by 9 days.

philipn / Anti-androgens for COVID-19 594b9071a6b8cce31f02ce6efc0ef6a156b82688

Possible mechanism of benefit in COVID-19

Clinical trial results

List of clinical trials

See also